Literature DB >> 6116511

Increased central 5-hydroxytryptamine receptor mechanisms in rats after chronic neuroleptic treatment.

D Dawbarn, S K Long, C J Pycock.   

Abstract

1 The behavioural responses of drugs known to act through central 5-hydroxytryptamine (5-HT) mechanisms have been investigated in rats receiving a neuroleptic (trifluoperazine) in their drinking water for 4 to 6 months.2 5-Hydroxytryptophan (5-HTP) induced 5-HT-dependent behaviours including head bobbing and lateral head weaving, reciprocal forepaw treading, tremor, backward walking, body writhing and ;wet-dog' shakes. In doses of 50 to 150 mg/kg, 5-HTP induced more intense behavioural effects in neuroleptic-treated rats than in the control animals.3 Similarly the putative 5-HT agonist, quipazine (1 to 20 mg/kg) and the 5-HT releasing drug, fenfluramine (5 to 20 mg/kg), both induced significantly greater motor responses in the chronically neuroleptic-treated rats.4 A 5-HT uptake inhibitor (femoxetine, 2.5 to 10 mg/kg) had little behavioural effect in either control or trifluoperazine-treated rats.5 Total specific high-affinity binding of radiolabelled 5-HT was significantly increased in crude membrane fractions prepared from the cortex, striatum and substantia nigra of neuroleptic-treated rats compared to control animals.6 High-affinity uptake of radiolabelled 5-HT into striatal slices was similar in experimental and control animals.7 Behavioural and biochemical data would indicate that postsynaptic 5-HT mechanisms are enhanced in rats treated chronically with trifluoperazine. Chronic neuroleptic therapy may thereby induce cerebral 5-HT receptor supersensitivity in addition to the well-documented cerebral dopamine receptor supersensitivity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6116511      PMCID: PMC2071833          DOI: 10.1111/j.1476-5381.1981.tb16784.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  The effects of quipazine on serotonin metabolism in rat brain.

Authors:  R W Fuller; H D Snoddy; K W Perry; B W Roush; B B Molloy; F P Bymaster; D T Wong
Journal:  Life Sci       Date:  1976-05-01       Impact factor: 5.037

2.  "Wet-dog" shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity.

Authors:  P Bedard; C J Pycock
Journal:  Neuropharmacology       Date:  1977-10       Impact factor: 5.250

3.  Effect of drugs on the tryptamine content of rat tissues.

Authors:  J M Saavedra; J Axelrod
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

4.  [Modification of the cerebral serotonin level in the rat by trifluoromethyl-2-phenyl ethyl aminopropane (Fenfluramine 768 S)].

Authors:  J Duhault; C Verdavainne
Journal:  Arch Int Pharmacodyn Ther       Date:  1967-12

5.  Serotonergic component of neuroleptic receptors.

Authors:  J E Leysen; C J Niemegeers; J P Tollenaere; P M Laduron
Journal:  Nature       Date:  1978-03-09       Impact factor: 49.962

6.  Comparative action of fenfluramine on the uptake and release of serotonin and dopamine.

Authors:  M H Kannengiesser; P F Hunt; J P Raynaud
Journal:  Eur J Pharmacol       Date:  1976-01       Impact factor: 4.432

7.  Butyrophenones and brain serotonin metaboism.

Authors:  M Grabowska
Journal:  Pol J Pharmacol Pharm       Date:  1976

8.  Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.

Authors:  D G Grahame-Smith
Journal:  J Neurochem       Date:  1971-06       Impact factor: 5.372

9.  High-affinity binding of (3H) 5-hydroxytryptamine to brain synaptosomal membranes: comparison with (3H) lysergic acid diethylamide binding.

Authors:  G M Fillion; J C Rousselle; M P Fillion; D M Beaudoin; M R Goiny; J M Deniau; J J Jacob
Journal:  Mol Pharmacol       Date:  1978-01       Impact factor: 4.436

10.  Behavioral evidence for the rapid release of CNS serotonin by PCA and fenfluramine.

Authors:  M E Trulson; B L Jacobs
Journal:  Eur J Pharmacol       Date:  1976-03       Impact factor: 4.432

View more
  4 in total

1.  Evaluation of sex differences in cannabinoid dependence.

Authors:  Julie A Marusich; Timothy W Lefever; Kateland R Antonazzo; Rebecca M Craft; Jenny L Wiley
Journal:  Drug Alcohol Depend       Date:  2014-02-12       Impact factor: 4.492

2.  The binding of [3H]-5-hydroxytryptamine to homogenates of human brain.

Authors:  E Dehlin; J Marcusson; C J Fowler; B Winblad
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

3.  Increased platelet membrane [3H]-LSD binding in patients on chronic neuroleptic treatment.

Authors:  M Schächter; D P Geaney; D G Grahame-Smith; P J Cowen; J M Elliott
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

Review 4.  Human platelet 5-hydroxytryptamine receptors: binding of [3H]-lysergic acid diethylamide (LSD). Effects of chronic neuroleptic and antidepressant drug administration.

Authors:  D G Grahame-Smith; D P Geaney; M Schachter; J M Elliott
Journal:  Experientia       Date:  1988-02-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.